Clinical Trial of Autologous Differentiated Adipocytes from Stem Cells Derived from Human Adipose Tissue

Authors


Address correspondence and reprint requests to: Sa Ik Bang, MD, Samsung Medical Center 50, Ilwon-dong, Gangnam-gu, Seoul, Korea 135-710, or e-mail: si55.bang@samsung.com

Abstract

BACKGROUND Adipose tissue–derived stem cells (ASCs) are considered to be a reliable cell source for the generation of adipose tissue because they can be differentiated into adipocytes. Previous data have indicated that adipogenic differentiation of ASCs before transplantation can enhance the regeneration of adipose tissue.

OBJECTIVE To evaluate the efficacy and safety of the use of autologous differentiated adipocytes for the treatment of depressed scars.

METHODS Autologous differentiated adipocytes were produced using well-established techniques, including the harvesting of stromal vascular fraction cells from lipoaspirates, expansion of ASCs, and differentiation into adipocytes. This was an open-label, dose-escalation study. Patients were given a subcutaneous injection of differentiated adipocytes and followed for 12 weeks.

RESULTS Thirty-one patients were injected with differentiated adipocytes. When the differentiated adipocytes were injected subcutaneously into depressed scars, the average recovery in volume was 74.6% at 12 weeks. Of 17 patients who completed the follow-up after determination of dose, seven were willing to enroll for extended follow-up. Long-term follow-up revealed that the recovery in volume at 12 weeks was maintained well for at least 1 year. There were no significant adverse events.

CONCLUSIONS The use of autologous differentiated adipocytes can be a safe and effective treatment for soft tissue defects, with relatively long-term maintenance of volume.

The authors have indicated no significant interest with commercial supporters.

Ancillary